Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) Enterprise Value: 2021-2025

Historic Enterprise Value for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $938.2 million.

  • Immunocore Holdings' Enterprise Value rose 43.06% to $938.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 billion, marking a year-over-year decrease of 8.30%. This contributed to the annual value of $655.6 million for FY2024, which is 77.66% down from last year.
  • Immunocore Holdings' Enterprise Value amounted to $938.2 million in Q3 2025, which was up 35.29% from $693.5 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Enterprise Value high stood at $2.9 billion for Q4 2023, and its period low was $648.5 million during Q1 2025.
  • Its 3-year average for Enterprise Value is $1.6 billion, with a median of $938.2 million in 2025.
  • As far as peak fluctuations go, Immunocore Holdings' Enterprise Value skyrocketed by 136.13% in 2022, and later slumped by 77.66% in 2024.
  • Quarterly analysis of 5 years shows Immunocore Holdings' Enterprise Value stood at $987.4 million in 2021, then soared by 136.13% to $2.3 billion in 2022, then climbed by 25.89% to $2.9 billion in 2023, then tumbled by 77.66% to $655.6 million in 2024, then skyrocketed by 43.06% to $938.2 million in 2025.
  • Its last three reported values are $938.2 million in Q3 2025, $693.5 million for Q2 2025, and $648.5 million during Q1 2025.